BidaskClub Lowers G1 Therapeutics (NASDAQ:GTHX) to Sell

G1 Therapeutics (NASDAQ:GTHX) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Tuesday, BidAskClub reports.

Several other analysts have also recently commented on GTHX. HC Wainwright reiterated a “buy” rating and issued a $72.00 target price on shares of G1 Therapeutics in a report on Wednesday, November 6th. Zacks Investment Research upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Needham & Company LLC set a $74.00 target price on G1 Therapeutics and gave the company a “buy” rating in a report on Monday, September 30th. Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. upgraded G1 Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the company from $38.00 to $45.00 in a report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. G1 Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $56.67.

Shares of GTHX stock opened at $20.86 on Tuesday. The business’s 50 day simple moving average is $22.23 and its 200 day simple moving average is $26.63. G1 Therapeutics has a one year low of $13.87 and a one year high of $41.80. The stock has a market capitalization of $811.76 million, a PE ratio of -8.15 and a beta of 2.17. The company has a debt-to-equity ratio of 0.03, a current ratio of 14.28 and a quick ratio of 14.28.

G1 Therapeutics (NASDAQ:GTHX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.86) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.01. As a group, research analysts expect that G1 Therapeutics will post -3.29 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of GTHX. DekaBank Deutsche Girozentrale lifted its stake in G1 Therapeutics by 63.5% in the second quarter. DekaBank Deutsche Girozentrale now owns 18,800 shares of the company’s stock valued at $585,000 after buying an additional 7,300 shares during the period. Swiss National Bank lifted its stake in G1 Therapeutics by 9.8% in the second quarter. Swiss National Bank now owns 48,400 shares of the company’s stock valued at $1,484,000 after buying an additional 4,300 shares during the period. State Board of Administration of Florida Retirement System acquired a new position in G1 Therapeutics in the second quarter valued at approximately $399,000. JPMorgan Chase & Co. lifted its stake in G1 Therapeutics by 27.8% in the second quarter. JPMorgan Chase & Co. now owns 1,429,138 shares of the company’s stock valued at $44,446,000 after buying an additional 310,614 shares during the period. Finally, Allianz Asset Management GmbH lifted its stake in G1 Therapeutics by 42.0% in the second quarter. Allianz Asset Management GmbH now owns 50,272 shares of the company’s stock valued at $1,541,000 after buying an additional 14,866 shares during the period. 77.78% of the stock is currently owned by hedge funds and other institutional investors.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

Read More: What is a back-end load?

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.